

CURRICULUM VITAE

PERSONAL INFORMATION

Name Manoj Vasant Murhekar
Father's name Vasant G. Murhekar
Office address ICMR National Institute of Epidemiology, R-127, TNHB,
Ayapakkam, Chennai, India-600 077
Phone/Fax : 91-44-26136201, Mobile: 91-9444414663
e-mail: mmurhekar@gmail.com, mmurhekar@nieicmr.org.in

EDUCATION

Date	College/Institute	Degree
7/1984-12/1989	Government Medical College, Nagpur, Nagpur university, Maharashtra, India	MBBS
3/1990-12/1992	Government Medical College, Nagpur, Nagpur university, Maharashtra, India	M.D. (Preventive and Social Medicine)
9/2007-10/2007	Sustainable Management Development Programme, Centre for Disease Control and Prevention, Atlanta, USA	Management for International Public Health

PROFESSIONAL POSITIONS

Period	Position held
2017	Director, National Institute of Epidemiology, ICMR, Chennai, India
2012-2016	Scientist G (Epidemiology), National Institute of Epidemiology, Chennai, India
2007-2012	Scientist F (Epidemiology), National Institute of Epidemiology, Chennai, India
2013 (Apr-Jun)	TAP, ESR-WPRO, WHO Regional Office for Western Pacific, Manila, Philippines
2011 (Jan-Jun)	WHO short term consultant, WHO country Office, Papua New Guinea
2004-2007	Deputy Director, National Institute of Epidemiology, Chennai, India
2001-2004	Deputy Director, Regional Medical Research Centre, ICMR, Port Blair, India
1998-2001	Assistant Director, Regional Medical Research Centre, ICMR, Port Blair, India
1993-1998	Senior Research Officer, Regional Medical Research Centre, Port Blair, India
1993	Lecturer, Department of Preventive and Social Medicine, Govt. Medical College, Nagpur, Maharashtra, India

AREAS OF INTEREST: Infectious disease epidemiology, vaccine preventable diseases, disease surveillance, outbreak investigations

MEMBERSHIP

1. Life member, Indian Association of Preventive and Social Medicine
2. Life member, IndiaClen
3. Advisory Board Member, Training Programs in Epidemiology and Public Health Interventions Network (TEPHINET)
4. National Taskforce, COVID-19
5. Tamil Nadu Technical Taskforce for COVID-19
6. Nagaland Technical Taskforce for COVID-19
7. Member, Scientific Advisory Committee, ICMR-National Institute of Medical Research, Delhi,
8. Member, Scientific Advisory Committee, ICMR-RMRC Gorakhpur,
9. Member, Scientific Advisory Committee, Malabar Cancer Centre, Thalassery, Kerala
10. Member, Board of Studies, TN MGR University, Chennai

RESEARCH:

Major research projects (as PI/Co-PI)	Funding agency
Prevalence of SARS-CoV-2 infection in India	ICMR, New Delhi
Effectiveness of COVID-19 vaccines against severe disease: A case control study	ICMR, New Delhi
Human Rabies and animal bite incidence survey, India.	ICMR, New Delhi
Developing guidelines for human surveillance for zoonotic influenza in swine-human interface	WHO, SEARO
Congenital Rubella Syndrome Surveillance	MoHFW, Govt of India
Model District for Public Health Preparedness, Surveillance and Response: Multi-Strategic Integrated Approach in Tiruvallur District, Tamil Nadu, India	CDC, Atlanta
Verification of sub-national claims for TB free status in India	Central TB Division
Incidence of dengue virus infection in India: A cohort study	ICMR, New Delhi
Prevalence and intensity of soil transmitted helminths in selected Indian states (Madhya Pradesh, Bihar, Uttar Pradesh, Chhattisgarh, Telangana and Tripura)	Deworm the World Initiative
Dengue infection in India: A systematic review and meta-analysis	DBT, New Delhi
Seroprevalence of dengue virus infection in India	ICMR, New Delhi
Aetiology of Acute encephalitis syndrome and acute differentiated febrile illness, Gorakhpur, Uttar Pradesh	ICMR, New Delhi
Vaccination coverage survey, Tamil Nadu	Govt of Tamil Nadu
Two-dose coverage of JE vaccine, Gorakhpur, Uttar Pradesh	ICMR, New Delhi
Measles case fatality ratio in Bihar	WHO, SEARO
Coverage & effectiveness of Japanese Encephalitis vaccine in Gorakhpur, Uttar Pradesh	ICMR, New Delhi

Temperature monitoring of the vaccine cold chain for assessing the level of freezing in Indian states	UNICEF, India
Hepatitis B infection among the tribes of Andaman and Nicobar Islands	MoHFW, Govt of India
Tuberculosis situation among the tribal population of Car Nicobar Island, India, 15 years after an intensified tuberculosis control project followed by implementation of the National Tuberculosis Programme	WHO, SEARO
Epidemiology of leptospirosis among the tribes of Andaman and Nicobar islands	ICMR, New Delhi
Lymphatic filariasis among the tribes of Andaman and Nicobar	ICMR, New Delhi
Safety and immunogenicity of intradermal administration of tissue culture anti-rabies vaccines	ICMR, New Delhi

HONORS/AWARDS/ACHIVEMENTS

Major General Saheb Singh Sokhey Award. Indian Council of Medical Research (2001:For outstanding contribution in the field of viral hepatitis among the tribal population of Andaman and Nicobar, India

PUBLICATIONS: 186

25 important papers in last five years highlighting significant contributions:

1. Murhekar MV et al. Prevalence of IgG Antibodies Against SARS-CoV-2 Among the General Population and Healthcare Workers in India, June–July 2021. (Preprint) <https://papers.ssrn.com/sol3/results.cfm>
2. Murhekar MV, et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021. *Int J Infect Dis.* 2021 Jul;108:145-155. doi: 10.1016/j.ijid.2021.05.040.
3. Murhekar MV et al. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. *Lancet Glob Health.* 2021 Mar;9(3):e257-e266. doi: 10.1016/S2214-109X(20)30544-1.
4. Murhekar MV et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. *Indian J Med Res.* 2020 Jul & Aug;152(1 & 2):48-60. doi: 10.4103/ijmr.IJMR_3290_20.
5. Murhekar MV et al. Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey. *Lancet Glob Health.* 2019 Aug;7(8):e1065-e1073. doi: 10.1016/S2214-109X(19)30250-5.
6. Murhekar MV et al. Immunity against diphtheria among children aged 5-17 years in India, 2017-18: a cross-sectional, population-based serosurvey. *Lancet Infect Dis.* 2021 Jun;21(6):868-875. doi: 10.1016/S1473-3099(20)30595-8
7. Santhosh Kumar M, Kamaraj P, Khan SA, Allam R, Barde PV, Dwibedi B, Kanungo S, Mohan U, Mohanty SS, Roy S, Sagar V, Savargaonkar D, Tandale BV, Topno RK, Girish Kumar CP, Sabarinathan R, Saravana Kumar V, Bitragunta S, Grover GS, Lakshmi PVM, Mishra CM, Sadhukhan P, Sahoo PK, Singh SK, Yadav CP, Ramya Dinesh E, Karunakaran T, Govindhasamy C, Daniel Rajasekar T, Jeyakumar A, Suresh A, Augustine D, Ashok Kumar P, Kumar R, Dutta S, Toteja GS, Gupta N, Clapham HE, Mehendale SM,

- Murhekar MV. Seroprevalence of chikungunya virus infection in India, 2017: a cross-sectional population-based serosurvey. *Lancet Microbe*. 2021, 2: e41-e47
8. Murhekar MV et al. Hepatitis-B virus infection in India: Findings from a nationally representative serosurvey, 2017-18. *Int J Infect Dis*. 2020 Nov;100:455-460. doi: 10.1016/j.ijid.2020.08.084.
 9. Shanmugasundaram D, Awasthi S, Dwibedi B, Geetha S, Jain M, Malik S, Patel B, Singh H, Tripathi S, Viswanathan R, Agarwal A, Bonu R, Jain S, Jena SK, Priyasree J, Pushpalatha K, Ali S, Biswas D, Jain A, Narang R, Madhuri S, George S, Kaduskar O, Kiruthika G, Sabarinathan R, Sapakal G, Gupta N, Murhekar MV. Burden of congenital rubella syndrome (CRS) in India based on data from cross-sectional serosurveys, 2017 and 2019-20. *PLoS Negl Trop Dis*. 2021 Jul 23;15(7):e0009608. doi: 10.1371/journal.pntd.0009608.
 10. Kumar CPG, Sugunan AP, Yadav P, Kurup KK, Aarathee R, Manickam P, Bhatnagar T, Radhakrishnan C, Thomas B, Kumar A, Jayasree J, Philomina B, Kumar KGS, Thulaseedharan NK, Gupta N, Rajendran R, Saritha RL, Mourya DT, Gangakhedkar RR, Murhekar MV. Infections among Contacts of Patients with Nipah Virus, India. *Emerg Infect Dis*. 2019 May;25(5):1007-1010. doi: 10.3201/eid2505.181352.
 11. Vivian Thangaraj JW, Mittal M, Verghese VP, Kumar CPG, Rose W, Sabarinathan R, Pandey AK, Gupta N, Murhekar M. Scrub Typhus as an Etiology of Acute Febrile Illness in Gorakhpur, Uttar Pradesh, India, 2016. *Am J Trop Med Hyg*. 2017 Nov;97(5):1313-1315. doi: 10.4269/ajtmh.17-0135.
 12. Jaiswal A, Subbaraj V, Vivian Thangaraj JW, **Murhekar MV**, Muliyl J. COVID-19 vaccine effectiveness in preventing deaths among high-risk groups in Tamil Nadu, India. *Indian J Med Res*. 2021 Jul 2. doi: 10.4103/ijmr.ijmr_1671_21.
 13. Thangaraj JW, Kumar MS, Kumar CG, Kumar VS, Kumar NP, Bhatnagar T, Ponnaiah M, Sabarinathan R, Sudharani D, Nancy A, Jagadeesan M, Babu S, **Murhekar M**. Persistence of humoral immune response to SARS-CoV-2 up to 7 months post-infection: Cross-sectional study, South India, 2020-21. *J Infect*. 2021 May 28:S0163-4453(21)00268-1. doi: 10.1016/j.jinf.2021.05.026.
 14. Murhekar MV, Vivian Thangaraj JW, Sadanandane C, Mittal M, Gupta N, Rose W, Sahay S, Kant R, Gupte MD. Investigations of seasonal outbreaks of acute encephalitis syndrome due to *Orientia tsutsugamushi* in Gorakhpur region, India: A One Health case study. *Indian J Med Res*. 2021 Mar;153(3):375-381.
 15. Murhekar MV, Clapham H. COVID-19 serosurveys for public health decision making. *Lancet Glob Health*. 2021 Mar 8:S2214-109X(21)00057-7. doi: 10.1016/S2214-109X(21)00057-7.
 16. Selvaraju S, Kumar MS, Thangaraj JW, Bhatnagar T, Saravanakumar V, Kumar CPG, Sekar K, Ilayaperumal E, Sabarinathan R, Jagadeesan M, Hemalatha MS, Murhekar MV. Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India. *Emerg Infect Dis*. 2021 Feb;27(2):586-589.
 17. Jeyashree K, Shanmugasundaram D, Rade K, Gangakhedkar RR, Murhekar MV. Impact and operational feasibility of TrueNat™ MTB/Rif under India's RNTCP. *Public Health Action*. 2020 Sep 21;10(3):87-91
 18. Thangaraj JW, Zaman K, Shete V, Pandey AK, Velusamy S, Deoshatwar A, Mittal M, Gupta N, Murhekar M. Effectiveness of Presumptive Treatment of Acute Febrile Illness With Doxycycline or Azithromycin in Preventing Acute Encephalitis Syndrome in Gorakhpur, India: A Cohort Study. *Indian Pediatr*. 2020 Jul 15;57(7):619-624.

19. Murhekar M, et al. Epidemiology of Congenital Rubella Syndrome (CRS) in India, 2016-18, based on data from sentinel surveillance. *PLoS Negl Trop Dis*. 2020 Feb 3;14(2):e0007982.
20. Chandni R, Renjith TP, Fazal A, Yoosef N, Ashhar C, Thulaseedharan NK, Suraj KP, Sreejith MK, Sajeeth Kumar KG, Rajendran VR, Remla Beevi A, Sarita RL, Sugunan AP, Arunkumar G, Mourya DT, Murhekar M. Clinical Manifestations of Nipah Virus-Infected Patients Who Presented to the Emergency Department During an Outbreak in Kerala State in India, May 2018. *Clin Infect Dis*. 2020 Jun 24;71(1):152-157.
21. Murhekar M, et al. Sentinel Surveillance for Congenital Rubella Syndrome - India, 2016-2017. *MMWR Morb Mortal Wkly Rep*. 2018 Sep 14;67(36):1012-1016. doi: 10.15585/mmwr.mm6736a4.
22. Ganeshkumar P, Murhekar MV, Poornima V, Saravanakumar V, Sukumaran K, Anandaselvasankar A, John D, Mehendale SM. Dengue infection in India: A systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2018 Jul 16;12(7):e0006618. doi: 10.1371/journal.pntd.0006618. eCollection 2018 Jul.
23. Mittal M, Bondre V, Murhekar M, Deval H, Rose W, Verghese VP, Mittal M, Patil G, Sabarinathan R, Thangaraj JWV, Kanagasabai K, Prakash JAJ, Gupta N, Gupte M, Gupte MD. Acute Encephalitis Syndrome in Gorakhpur, Uttar Pradesh, 2016: Clinical and Laboratory Findings. *Pediatr Infect Dis J*. 2018 May 9.
24. Thangaraj JWV, Vasanthapuram R, Machado L, Arunkumar G, Sodha SV, Zaman K, Bhatnagar T, Hameed SKS, Kumar A, Abdulmajeed J, Velayudhan A, Deoshatwar A, Desai AS, Kumar KH, Gupta N, Laserson K, Murhekar M; Scrub Typhus Risk Factor Study Group. Risk Factors for Acquiring Scrub Typhus among Children in Deoria and Gorakhpur Districts, Uttar Pradesh, India, 2017. *Emerg Infect Dis*. 2018 Dec;24(12):2364-2367.
25. Mittal M, Thangaraj JWV, Rose W, Verghese VP, Kumar CPG, Mittal M, Sabarinathan R, Bondre V, Gupta N, Murhekar MV. Scrub Typhus as a Cause of Acute Encephalitis Syndrome, Gorakhpur, Uttar Pradesh, India. *Emerg Infect Dis*. 2017 Aug;23(8):1414-1416.